Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Neurocrine to $115 from $120 and keeps an Equal Weight rating on the shares. The firm notes 2023 seems to be a transition year as Neurocrine looks to diversify beyond Ingrezza. OpEx investment to do so may offset impact of Ingrezza growth to EPS. In this backdrop, crinecerfont data and POC readouts will be key catalysts for the stock in the second half of 2023, Wells says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target lowered to $127 from $132 at Cantor Fitzgerald
- Neurocrine price target raised to $131 from $125 at Wedbush
- Neurocrine price target lowered to $131 from $133 at Citi
- Neurocrine price target lowered to $131 from $136 at Barclays
- Neurocrine price target lowered to $95 from $103 at Piper Sandler